Asset
BIZALIMOGENE RALAPLASMID
Inovio Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01304524 | phase2 | completed | 2011-04-01 | 2014-05-01 | Inovio Pharmaceuticals | A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3 |
| NCT03180684 | phase2 | completed | 2017-08-31 | 2020-07-23 | Inovio Pharmaceuticals | Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3) |
| NCT01188850 | phase1 | completed | 2010-07-01 | 2011-10-01 | Inovio Pharmaceuticals | Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100 |
| NCT00685412 | phase1 | completed | 2008-05-01 | 2011-01-01 | Inovio Pharmaceuticals | Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3 |
| NCT03185013 | phase3 | completed | 2017-06-28 | 2020-07-08 | Inovio Pharmaceuticals | REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) |
FDA applications (0)
This company has no applications containing this asset.